A point-of-care, microfluidics-based approach for multiplexed detection of biomarkers in unprocessed blood using a surface plasmon resonance sensor

一种基于微流体的即时护理方法，使用表面等离子共振传感器对未处理的血液中的生物标志物进行多重检测

• 批准号: 556618-2020
• 负责人: Poudineh, Mahla
• 金额: $ 3.92万
• 依托单位: University of Waterloo
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705548
• 关键词: point; care; microfluidics; based; approach

Affinité Instruments, a Montréal-based start-up, is developing a low-cost, point-of-care (POC) device for rapid detection of COVID-19 antibodies using whole blood sample. As the relationship between antibodies and immunity to infection with the novel severe acute respiratory syndrome coronavirus (SARS-COV-2) is still unknown, detection of antibodies can be used to assess previous exposure to pathogens. In the proposed project, the detection of antibodies will be performed by using a surface plasmon resonance (SPR) device integrated with a microfluidic sample preparation platform. The SPR device is a key bioanalytical method in biosensing application, antibody characterization, and drug discovery and development. SPR sensor that is functionalized with anti-human immunoglobin (IgG, IgM, and IgA) antibodies can be used to detect anti-SARS-CoV-2 antibodies in the nanomolar range. To develop a next-generation SPR product for clinical testing of COVID-19 antibodies, there is a need to design a customized microfluidic platform to separate plasma from whole blood to enable direct blood testing. In this project, Affinité Instruments teams up with Poudineh group (expert in microfluidic device design and fabrication for biomedical application) at the University of Waterloo to develop a custom designed microfluidic platform that can be integrated with SPR sensor. Using a plasma separation membrane, the pump-free microfluidic filtration device will separate plasma in less than 10 min. The collected plasma will be directly sent to SPR which will determine the levels of COVID-19 antibodies in the blood. The proposed POC device will offer a rapid diagnosis in less than 10 min from whole blood and will be more accurate than any existing testing technologies. This novel detection technology will limit the spread of virus and the success of this study will have potential impact in recovering Canadian and global economies.

总部位于蒙塔梅萨的初创公司affinit<e:1> Instruments正在开发一种低成本的即时护理设备，用于使用全血样本快速检测COVID-19抗体。由于抗体与新型严重急性呼吸综合征冠状病毒（SARS-COV-2）感染免疫之间的关系尚不清楚，抗体检测可用于评估既往病原体暴露情况。